Acrux Limited ( (AU:ACR) ) has shared an update.
Acrux Limited reported a significant decline in revenues from ordinary activities, down 70% to $1.71 million for the half-year ended December 31, 2024. The company also experienced a 6% increase in net loss, totaling $3.425 million, with no dividends declared or paid during this period. This financial downturn reflects challenges in Acrux’s market positioning and could have implications for its stakeholders, as the net tangible asset per ordinary security also decreased from $0.02 to $0.01.
More about Acrux Limited
Acrux Limited operates in the pharmaceutical industry, focusing on the development and commercialization of specialty topical pharmaceuticals. The company is known for its transdermal drug delivery technology, which targets both local and systemic conditions.
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $7.77M
See more data about ACR stock on TipRanks’ Stock Analysis page.